Study of YF087 for advanced solid tumors with MSI-H or dMMR
Part of Cancer clinical trials.
This trial tests a new drug called YF087 in people with advanced solid tumors that have a specific genetic feature (MSI-H or dMMR). It may help if your cancer has grown despite previous treatment, including a PD-1/PD-L1 inhibitor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced solid tumor that cannot be removed by surgery or has spread to other parts of the body.
- Your tumor has a genetic marker called MSI-H or dMMR (your doctor can test for this).
- Your cancer has progressed after your most recent treatment, and you have already tried a PD-1 or PD-L1 inhibitor (a type of immunotherapy).
- You have at least one measurable tumor that can be seen on a CT or MRI scan.
- You are physically active and able to take care of yourself (ECOG score of 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental pill (FS-207) for people with advanced solid tumors that have a specific genetic marker called MSI-H (high microsatellite instability) or dMMR. If you have already had immunotherapy that didn't work, this drug might help by attacking cancer cells in a new way.
This trial tests an experimental drug called FXB0871 in people with advanced solid tumors that have stopped responding to standard treatments or for whom no standard treatment exists. The goal is to see if the drug is safe and effective, and patients who enroll will receive close monitoring throughout the study.
This trial tests an experimental drug called FXS887 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if FXS887 can help shrink or control the tumor.
This trial tests a new drug called FH-006 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
This study tests an experimental drug called YL217 in people with advanced solid tumors that have not responded to other treatments. The drug may work by targeting a protein on cancer cells and delivering a chemotherapy-like agent directly to the tumor, potentially slowing or stopping its growth.
This trial tests an experimental drug for people with advanced solid tumors, including small cell lung cancer, that have stopped responding to standard treatments. The goal is to find out if the drug is safe and effective.
Hear when a new Advanced Solid Tumor Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.